by Hanna | Jun 12, 2024 | Blog Post
Recently, Federal Trade Commission (FTC) Chair Lina Khan appeared before the House Appropriations Committee Subcommittee on Financial Services and General Government to discuss the Agency’s proposed budget for the upcoming fiscal year. During her testimony, Chair Khan...
by Hanna | Jun 5, 2024 | Blog Post, Innovations Advanced by M&A
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series...
by Hanna | May 30, 2024 | Blog Post
In a recent policy brief, Satya Marar, a fellow at the Mercatus Center at George Mason University, points out the considerable harm that the Federal Trade Commission (FTC) and Department of Justice’s (DOJ) recent approach to antitrust enforcement is having on...
by Hanna | May 22, 2024 | Blog Post
The United States is home to thousands of life sciences companies, with hundreds more starting every year, each competing to develop and deliver innovations to patients. Nearly 80% of these companies operate without a profit, even as the average cost of bringing a new...
by Hanna | May 21, 2024 | Blog Post, PULSE Partner
How mergers and acquisitions drive innovative cures and New Jersey’s economy New Jersey has long been home to some of the world’s leading research-based biopharmaceutical companies. Many have made New Jersey a base for their global, North American, or U.S. operations....
by Hanna | May 15, 2024 | Blog Post, Innovations Advanced by M&A
This blog is another installment in a series, Innovations Advanced by M&A, that underscores the importance of mergers and acquisitions in ensuring a competitive and vibrant biopharmaceutical landscape for patients. You can find previous blogs in this series here:...
